Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating reiterated by equities researchers at BMO Capital Markets in a research note issued on Monday, TipRanks reports.

A number of other brokerages have also recently issued reports on AMGN. Piper Jaffray Companies upped their price objective on shares of Amgen from $210.00 to $218.00 and gave the company an “overweight” rating in a research note on Monday, August 26th. JPMorgan Chase & Co. set a $198.00 target price on shares of Amgen and gave the stock a “hold” rating in a research report on Friday, September 6th. Morgan Stanley lowered their price target on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Royal Bank of Canada boosted their price target on shares of Amgen from $192.00 to $206.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 27th. Finally, Cowen set a $231.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Thursday, August 22nd. Eleven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $217.33.

NASDAQ:AMGN traded down $1.03 during mid-day trading on Monday, reaching $195.84. The stock had a trading volume of 2,837,132 shares, compared to its average volume of 3,050,802. The stock has a market capitalization of $121.34 billion, a P/E ratio of 13.60, a P/E/G ratio of 2.37 and a beta of 1.11. The firm has a 50 day moving average price of $196.19 and a two-hundred day moving average price of $185.15. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. Amgen has a one year low of $166.30 and a one year high of $211.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period last year, the business earned $3.83 earnings per share. Research analysts forecast that Amgen will post 14.3 earnings per share for the current year.

In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total transaction of $413,400.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Cynthia M. Patton sold 13,426 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the sale, the senior vice president now owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The disclosure for this sale can be found here. In the last three months, insiders sold 17,851 shares of company stock worth $3,659,900. Insiders own 0.25% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Landsberg Bennett & Dubbaneh LLC raised its holdings in shares of Amgen by 19.2% during the first quarter. Landsberg Bennett & Dubbaneh LLC now owns 1,941 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 313 shares in the last quarter. Cascade Investment Advisors Inc. increased its position in Amgen by 1.1% during the 1st quarter. Cascade Investment Advisors Inc. now owns 7,100 shares of the medical research company’s stock valued at $1,349,000 after purchasing an additional 75 shares during the period. CRA Financial Services LLC raised its holdings in Amgen by 5.6% in the 1st quarter. CRA Financial Services LLC now owns 1,165 shares of the medical research company’s stock worth $221,000 after purchasing an additional 62 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in Amgen by 55.9% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 725 shares of the medical research company’s stock worth $138,000 after purchasing an additional 260 shares in the last quarter. Finally, Portland Global Advisors LLC lifted its position in shares of Amgen by 0.8% in the 1st quarter. Portland Global Advisors LLC now owns 15,059 shares of the medical research company’s stock worth $2,861,000 after purchasing an additional 122 shares during the period. 76.28% of the stock is currently owned by institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Dividend Aristocrat Index

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.